SAN FRANCISCO, CA--(Marketwired - September 13, 2017) - Cantabio Pharmaceuticals, Inc. CTBO, a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's, Parkinson's and other related neurodegenerative diseases, today announced that its CEO, Dr Gergely Tóth, will present at the 2017 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai, China on September 14, 2017 at 4:15pm, 2^nd floor Main Building, Intercontinental Shanghai Rujin. Dr Tóth will present a company update with a summary of the latest research findings from the company's CB101 and CB201 programs targeting the DJ-1 protein for the treatment of Alzheimer's and Parkinson's, and will report on the potential application of CB101 candidates in protecting from methylglyoxal activity, as found in type 2 diabetes.

About Cantabio Pharmaceuticals, Inc.

Cantabio is focused on bringing novel, first-in-class drug candidates into clinical trials and beyond through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics, focusing on protein systems implicated in neurodegenerative disorders, including Alzheimer's and Parkinson's, and oxidative stress. The company is currently engaged in advanced pre-clinical trials of its therapeutic candidates. More information is available at www.cantabio.com.

Forward-Looking Statements:

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.